LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis

Photo from wikipedia

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg‐Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)‐associated small vessel vasculitis. It is a multisystem disorder and can affect every… Click to show full abstract

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg‐Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)‐associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.

Keywords: granulomatosis polyangiitis; eosinophilic granulomatosis; pediatric patient

Journal Title: Pediatric Pulmonology
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.